Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy.
Anticoagulation
Atrial fibrillation
Bleeding
Ischemic stroke
Thrombocytopenia
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
19
01
2021
pubmed:
2
2
2021
medline:
28
1
2022
entrez:
1
2
2021
Statut:
ppublish
Résumé
Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We aimed to identify anticoagulation management strategies and evaluate bleeding and thrombosis rates associated with each approach. A retrospective cohort study in Israel and the Netherlands was conducted. Patients with hematological malignancy and atrial fibrillation were indexed when platelets were < 50 × 10
Identifiants
pubmed: 33523384
doi: 10.1007/s11239-021-02393-8
pii: 10.1007/s11239-021-02393-8
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
590-596Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Hu YF, Liu CJ, Chang PMH, Tsao HM, Lin YJ, Chang SL, Lo LW, Tuan TC, Li CH, Chao TF, Chung FP, Liao JN, Chen TJ, Chen SA (2013) Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 165:355–357. https://doi.org/10.1016/j.ijcard.2012.08.036
doi: 10.1016/j.ijcard.2012.08.036
Farmakis D, Parissis J, Filippatos G (2014) Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 63:945–953. https://doi.org/10.1016/j.jacc.2013.11.026
doi: 10.1016/j.jacc.2013.11.026
Mathur P, Paydak H, Thanendrarajan S, Van Rhee F (2016) Atrial fibrillation in hematologic malignancies, especially after autologous hematopoietic stem cell transplantation: review of risk factors, current management, and future directions. Clin Lymphoma Myeloma Leuk 16:70–75. https://doi.org/10.1016/j.clml.2015.10.001
doi: 10.1016/j.clml.2015.10.001
Conen D, Wong JA, Sandhu RK, Cook NR, Lee IM, Buring JE, Albert CM (2016) Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol 1:389–396. https://doi.org/10.1001/jamacardio.2016.0280
doi: 10.1001/jamacardio.2016.0280
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 137:263–272. https://doi.org/10.1378/chest.09-1584
doi: 10.1378/chest.09-1584
Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH, Andresen D, Camm AJ, Davies W, Capucci A, Lévy S, Olsson B, Aliot E, Breithardt G, Cobbe S, Le Heuzey JY, Santini M, Vardas P, Manini M, Bramley C, Laforest V, Taylor C, Del Gaiso S, Huber K, De Backer G, Sirakova V, Cerbak R, Thayssen P, Lehto S, Blanc JJ, Delahaye F, Kobulia B, Zeymer U, Cokkinos D, Karlocai K, Graham I, Shelley E, Behar S, Maggioni A, Gonçalves L, Grabauskiene V, Asmussen I, Deckers J, Stepinska J, Mareev V, Vasiljevic Z, Riecansky I, Kenda MF, Alonso A, Lopez-Sendon JL, Rosengren A, Buser P, Okay T, Sychov O, Fox K, Schofield P, Simoons M, Wood D, Battler A, Boersma E, Fox K, Komajda M, McGregor K, Mulder B, Priori S, Rydén L, Vahanian A, Wijns W, Sanofi-Aventis, Grigoryan SV, Apetyan I, Aroyan S, Azarapetyan L, Anvari A, Gottsauner-Wolf M, Pfaffenberger S, Aydinkoc K, Kalla K, Penka M, Drexel H, Langer P, Pierard LA, Legrand V, Blommaert D, Schroeder E, Mancini I, Geelen P, Brugada P, De Zutter M, Vrints C, Vercammen M, Morissens M, Borisov B, Petrov VA, Marinova M, Assen A, Goudev R, Peychev Y, Stoyanovsky V, Stoynev E, Kranjcevic S, Moutiris J, Ioannides M, Evequoz D, Spacilova J, Novak M, Eisenberger M, Mullerova J, Kautzner J, Riedlbauchova L, Petru` J, Taborsky M, Cappelen H, Sharaf YA, Ibrahim BSS, Tammam K, Saad A, Elghawaby H, Sherif HZ, Farouk H, Mielke A, Engelen M, Kirchhof P, Zimmermann P, Aviles FF, Rubio J, Malpartida F, Corona M, Sanchez LT, Miguel J, Herrera L, Quesada A, Garcia AJM, Gonzalez CS, Juango MSA, Berjon-Reyero J, Alegret JM, Fernandez JMC, Carrascosa C, Romero RAF, Lara MG, Sendon JLL, de Diego JJG, Martin LS, Irurita M, Guttierez NH, Rubio JRS, Antorrena I, Paves AB, Salvador A, Orriach MD, Garcia AA, Epelde F, Martinez VB, Sanchez AB, Galvez CP, Rivero RF, Madrid AH, Baron-Esquivias G, Peinado R, Guindal JAG, Vera TR, Fernandez EL, Gayan R, Garcia J, Bodegas A, Lopez JT, Florez JM, Cabezas CL, de Castroviejo EVR, Bellido JM, Ruiz ME, Savolainen K, Nieminen M, Toivonen L, Syvanne M, Pietila M, Galley D, Beltra C, Gay A, Daubert JC, Lecocq G, Poulain C, Cleland JGFC, Shelton R, Choudhury A, Abuladze G, Jashi I, Tsiavou A, Giamouzis G, Dagres N, Kostopoulou A, Tsoutsanis D, Stefanadis C, Latsios G, Vogiatzis I, Gotsis A, Bozia P, Karakiriou M, Koulouris S, Parissis J, Kostakis G, Kouris N, Kontogianni D, Athanasios K, Douras A, Tsanakis T, Marketou M, Patsourakos N, Czopf L, Halmosi R, Préda I, Csoti E, Badics A, Strasberg B, Freedberg NA, Katz A, Zalzstein E, Grosbard A, Goldhammer E, Nahir M, Epstein M, Vider I, Luria D, Mandelzweig L, Aloisi B, Cavallaro A, Antonielli E, Doronzo B, Pancaldo D, Mazzola C, Buontempi L, Calvi V, Giuffrida G, Figlia A, Ippolito F, Gelmini GP, Gaibazzi N, Ziacchi V, De Tommasi F, Lombardi F, Fiorentini C, Terranova P, Maiolino P, Albunni M, Pinna-Pintor P, Fumagalli S, Masotti G, Boncinelli L, Rossi D, Santoro GM, Fioranelli M, Naccarella F, Maranga SS, Lepera G, Bresciani B, Seragnoli E, Forti MC, Cortina V, Baciarello G, Cicconetti P, Lax A, Vitali F, Igidbashian D, Scarpino L, Terrazzino S, Tavazzi L, Cantu F, Pentimalli F, Novo S, Coppola G, Zingarini G, Ambrozio G, Moruzzi P, Callegari S, Saccomanno G, Russo P, Carbonieri E, Paino A, Zanetta M, Barducci E, Cemin R, Rauhe W, Pitscheider W, Meloni M, Marchi SM, Di Gennaro M, Calcagno S, Squaratti P, Quartili F, Bertocchi P, De Martini M, Mantovani G, Komorovsky R, Desideri A, Celegon L, Tarantini L, Catania G, Lucci D, Bianchini F, Puodziukynas A, Kavoliuniene A, Barauskiene V, Aidietis A, Barysiene J, Vysniauskas V, Zukauskiene I, Kazakeviciene N, Georgievska-Ismail L, Poposka L, Vataman E, Grosu AA, op Reimer WS, de Swart E, Lenzen M, Jansen C, Brons R, Tebbe H, van Hoogenhuyze DCA, Veerhoek MJ, Kamps M, Haan D, van Rijn N, Bootsma A, Baur L, van den A, Fransen H, Eurlings L, Meeder J, De Boer MJ, Winter J, Broers H, Werter C, Bijl M, Versluis S, Milkowska M, Wozakowska-Kaplon B, Janion M, Lepska L, Swiatecka G, Kokowicz P, Cybulski J, Gorecki A, Szulc M, Rekosz J, Manczak R, Wnuk-Wojnar AM, Trusz-Gluza M, Rybicka-Musialik A, Myszor J, Szpajer M, Cymerman K, Sadowski J, Sniezek-Maciejewska M, Ciesla-Dul M, Gorkiewicz-Kot I, Grodzicki T, Rewiuk K, Kubik L, Lewit J, de Sousa JMFR, Ferreira R, Freitas A, Morais JCA, Pires R, Gomes MJV, Gago P, Candeias RAC, Nunes L, Sa JVM, Ventura M, de Oliveira M, Alves LB, Bostaca I, Olariu CT, Dan GA, Dan A, Podoleanu C, Frigy A, Georgescu GIM, Arsenescu C, Statescu C, Sascau R, Dimitrascu DL, Rancea R, Shubik YV, Duplyakov D, Shalak M, Danielyan M, Galyavich A, Zakirova V, Hatala R, Kaliska G, Kmec J, Zupan I, Tasiè J, Vokac D, Edvardsson N, Poci D, Gamra H, Denguir H, Sepetoglu A, Arat-Ozkan A, Orynchak M, Paliy E, Vakalyuk I, Malidze D, Prog R, Yabluchansky MI, Makienko NV, Potpara T, Knezevic S, Randjelovic M (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. https://doi.org/10.1378/chest.10-0134
doi: 10.1378/chest.10-0134
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2019.01.011
doi: 10.1016/j.jacc.2019.01.011
Lip GYH, Lane DA (2015) Stroke prevention in atrial fibrillation: a systematic review. JAMA 313(19):1950–1962
doi: 10.1001/jama.2015.4369
Patell R, Gutierrez A, Rybicki L, Khorana AA (2017) Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol. https://doi.org/10.1016/j.amjcard.2017.08.038
doi: 10.1016/j.amjcard.2017.08.038
Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, Norfolk D, Copplestone A, Smith N, Kerr P, Jones G, Raj K, Westerman DA, Szer J, Jackson N, Bardy PG, Plews D, Lyons S, Bielby L, Wood EM, Murphy MF (2013) A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. https://doi.org/10.1056/NEJMoa1212772
doi: 10.1056/NEJMoa1212772
Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. https://doi.org/10.1182/blood-2002-01-0108
doi: 10.1182/blood-2002-01-0108
Liebman HA (2014) Thrombocytopenia in cancer patients. Thromb Res 133:S63–S69. https://doi.org/10.1016/S0049-3848(14)50011-4
doi: 10.1016/S0049-3848(14)50011-4
Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. https://doi.org/10.1001/archinte.166.4.458
doi: 10.1001/archinte.166.4.458
Gerber DE, Segal JB, Yair Levy M, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood. https://doi.org/10.1182/blood-2007-10-117051
doi: 10.1182/blood-2007-10-117051
Wang TY, Ou FS, Roe MT, Harrington RA, Ohman EM, Gibler WB, Peterson ED (2009) Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.108.827162
doi: 10.1161/CIRCULATIONAHA.108.827162
Caro J, Navada S (2018) Safety of anticoagulation in patients with atrial fibrillation and MDS/AML complicated by thrombocytopenia: an unresolved challenge: can they be managed ? A report of three cases and literature review. Am J Hematol. https://doi.org/10.1002/ajh.25045
doi: 10.1002/ajh.25045
Leader A, ten Cate H, Spectre G, Beckers EAM, Falanga A (2018) Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps. Crit Rev Oncol Hematol 132:76–88
doi: 10.1016/j.critrevonc.2018.09.014
Khanal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, Maness LJ, Lunning MA, Gundabolu K, Bhatt VR (2016) Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol. https://doi.org/10.1002/ajh.24526
doi: 10.1002/ajh.24526
Samuelson Bannow BT, Walter RB, Gernsheimer TB, Garcia DA (2017) Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis 44:442–447. https://doi.org/10.1007/s11239-017-1539-4
doi: 10.1007/s11239-017-1539-4
Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. https://doi.org/10.1111/jth.14015
doi: 10.1111/jth.14015
Easaw JC, Shea-Budgell MA, Wu CMJ, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, Macneil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, Tagalakis V, Welch S, Kavan P (2015) Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol. https://doi.org/10.3747/co.22.2587
doi: 10.3747/co.22.2587
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM (2018) NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2018.0084
doi: 10.6004/jnccn.2018.0084
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AGG, Hasselblad V, Ortel TL (2015) Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. https://doi.org/10.1056/NEJMoa1501035
doi: 10.1056/NEJMoa1501035
National Institute of Health (2017) National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. NIH Publ. https://doi.org/10.1080/00140139.2010.489653
doi: 10.1080/00140139.2010.489653
Schulman S, Kearon C, Haemostasis. on behalf of the S on C of A of the S and SC of the IS on T (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost. https://doi.org/10.1111/j.1538-7836.2009.03678.x
doi: 10.1111/j.1538-7836.2009.03678.x
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126. https://doi.org/10.1111/jth.13140
doi: 10.1111/jth.13140
Rechenmacher SJ, Fang JC (2015) Bridging anticoagulation primum non nocere. J Am Coll Cardiol 66:1392–1403. https://doi.org/10.1016/j.jacc.2015.08.002
doi: 10.1016/j.jacc.2015.08.002
Kopolovic I, Lee AYY, Wu C (2015) Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol. https://doi.org/10.1007/s00277-014-2198-6
doi: 10.1007/s00277-014-2198-6
NCT03195010 Management of platelet transfusion therapy in patients with blood cancer or treatment-induced thrombocytopenia. https://clinicaltrials.gov/show/NCT03195010 . https://doi.org/10.1002/CENTRAL/CN-01588762